๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Immunovia AB (publ) (STO:IMMNOV)
Sweden flag Sweden ยท Delayed Price ยท Currency is SEK
0.0371
+0.0042 (12.77%)
Nov 19, 2026, 2:14 PM CET

Immunovia AB Earnings Call Transcripts

Fiscal Year 2026

  • Q3 net sales rose to SEK 843,000 and operating loss narrowed to SEK 17.7m; PancreaSure reached 36 surveillance programs, including 12 at full adoption. A highly dilutive rights issue aims to fund operations through Q2 2027, while Medicare coverage review and partner discussions progress.

  • Investor update

    PancreaSure reported 77.6% sensitivity for stage 1โ€“2 disease and adoption across 36 high-risk surveillance programs. Medicare coverage review is underway, while a SEK 64m rights issue is intended to fund commercialization and studies into Q3 2027.

  • PancreaSure adoption expanded to 27 high-risk programs, driving over 300% sales growth year-over-year. Cash burn remains below guidance, with operations funded into Q4 2026. Medicare and New York State coverage submissions are key near-term catalysts.

  • Q1 2026 saw 169% revenue growth and improved operating loss, driven by increased PancreaSure adoption and disciplined cost control. Strategic focus remains on expanding U.S. market penetration, securing reimbursement, and forming commercialization partnerships, with a strong cash position supporting operations through Q3 2026.

Fiscal Year 2025

  • PancreaSure launched in Q4 2025 with early adoption at 12 centers and strong clinical validation. Revenue remains modest, but a SEK 69.8 million rights issue extends cash runway through Q3 2026. Medicare coverage submission is planned for mid-2026, with significant revenue expected in 2027.

  • PancreaSure's commercial launch marked a major milestone, with rapid adoption by leading cancer centers and strong clinical validation. Financial discipline reduced cash burn, and a successful rights issue secured funding into 2026. Medicare reimbursement progress and further clinical studies are key next steps.

  • PancreaSure's launch marks a pivotal step, with strong scientific validation and initial adoption by top U.S. centers. Q2 saw reduced expenses and a successful rights issue to fund commercialization and reimbursement studies, with revenue expected to shift from patient pay to insurance by 2027.

  • Transitioning to commercialization, the PancreaSure test is set for a September 2025 launch, showing strong clinical performance and doubling its addressable market. Cash reserves are expected to last through Q3, with ongoing efforts to secure partnerships and reimbursement.

  • Study update

    A clinical validation study in high-risk individuals showed a next-generation blood test detects early-stage pancreatic cancer with 77% sensitivity and 88% specificity, outperforming standard imaging and CA 19-9. Combined with prior data, results support reimbursement, regulatory approval, and a targeted US launch in Q3 2025.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021

Fiscal Year 2020